Search
Afamelanotide
go.drugbank.com/drugs/DB04931ApprovedA187202,A187205] Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 2014[L9119] and subsequent FDA
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … [L2932] In July 2025, the FDA expanded approval to include a new pediatric formulation, Doptelet Sprinkle (avatrombopag oral granules), specifically designed for children aged one to less than six years
Biotin
go.drugbank.com/drugs/DB00121ApprovedInvestigationalNutraceuticalA water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.
Mixtures: Nephron FA, Nephron FACaffeine
go.drugbank.com/drugs/DB00201ApprovedInvestigational[T716] The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999.
Mixtures: Ara Menstrual CompleteEnrofloxacin
go.drugbank.com/drugs/DB11404InvestigationalVet approvedEnrofloxacin is approved by the FDA for its veterinary use. … Due to the identification of fluoroquinolone-resistant strains of _Campylobacter_, in September 2005, the FDA withdrew the approval of enrofloxacin for its use in water to treat flocks of poultry.
Tarlatamab
go.drugbank.com/drugs/DB17256ApprovedInvestigational[L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific
Veligrotug
go.drugbank.com/drugs/DB18976Approved[L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929]
Turoctocog alfa
go.drugbank.com/drugs/DB09109Approved[A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.